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ABSTRACT 
The characterization of a new class of hydrophilic liver-targeted agents for gamma-
scintigraphy and MRI, consisting, respectively, of [153Sm]3+ or Gd3+ complexes of DOTA 
monoamide or bisamide linked glycoconjugates (DOTA = 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid), is reported. In vitro studies show high uptake of radiolabeled 
153SmDOTAGal2 by the human hepatocyte carcinoma cell line Hep G2 containing the 
asialoglycoprotein receptor (ASGP-R), which is decreased to less than 50 % by the 
presence of its high affinity ligand asialofetuin (ASF). In vivo biodistribution, gamma-
imaging and pharmaco-kinetic studies on Wistar rats using the [153Sm]3+-radiolabeled 
conjugates show an high uptake in the receptor-rich organ liver of the compounds 
containing terminal galactosyl groups, but very little uptake for those with terminal 
glycosyl groups. Blocking the receptor in vivo reduced liver uptake by 90%, strongly 
suggesting that the liver uptake of these compounds is mediated by their binding to the 
asyaloglycoprotein receptor (ASGP-R). This study also demonstrated that the valency 
increase improves the targeting capability of the glycoconjugates, which is also affected by 
their topology. However despite the specific liver uptake of the radiolabeled galactose-
bearing multivalent compounds, the animal MRI assessment of the corresponding Gd3+ 
chelates shows liver-to-kidney contrast effects which are not significantly better than those 
shown by GdDTPA. The maximum concentration/dose ratio attained in the kidneys by the 
Gd3+- based CAs is considerably lower than for GdDTPA, indicating that part of the 
injected CAs is T1 contrast-silent, presumably when taken up into the liver. The T1 
shortening effect of the Gd3+-labeled Gal-containing compounds is probably strongly 
diminished upon hepatocyte internalization into an endossomic vesicle via receptor-
mediated endocytosis of the ASGP-R. 
Keywords: magnetic resonance imaging; contrast agents; gadolinium; glycoconjugates, 
liver targeting, asialoglycoprotein receptor, gamma scintigraphy
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INTRODUCTION 
In humans and animals, oligosacharides are covalently bound to proteins 
(glycoproteins) and lipids (glycolipids) and control a wide variety of cellular processes. 
These functions are mediated by a class of membrane receptor proteins belonging to the 
general family of lectins. Lectins are monomeric or (homo/hetero)-oligomeric proteins, 
either soluble or membrane-bound, bearing a single or multiple carbohydrate recognizing 
domain(s) (CRD) per subunit (1,2). The CRDs interact specifically with sugars (glucose, 
mannose, galactose, etc) with affinity constants (lectin-monomeric sugar) (Kd) in the 
milimolar range (3). Assembly of monomeric units produces oligomeric lectins displaying 
an array of CRDs with a variety of topologies (4). Often one or both of the interacting 
sugar/lectin partners are membrane-bound. A membrane-bound lectin (receptor) may 
recognize a soluble or a membrane-bound oligosaccharide (5). Both types of interactions 
are appealing for pharmacologic intervention as long as the intrinsically low monomeric 
sugar-lectin affinity can be overcome (6). The use of soluble multivalent glycoconjugate 
constructs displaying a cluster glycosid effect is mandatory for the targeting of cell/organ-
specific lectins for drug delivery purposes and for the inhibition of cell-cell or cell-foreign 
body (bacteria/virus) interactions (7, 8). The hepatic asialoglycoprotein receptor (ASGP-R) 
is an organ-specific lectin, not found anywhere else in the body except on the surface of 
hepatocytes. This hetero-oligomeric lectin has affinity for terminal β-galactoside and β-N-
acetyl-galactosaminyl residues on glycoproteins. Although its precise function in vivo is 
still unclear, it is involved in selectively removing de-sialylated glycoproteins, with 
exposed terminal galactose residues, from serum (9). In addition to asialoglycoproteins, the 
ASGP-R recognises β-galactoside and N-acetyl-β-galactosaminyl residues appended to a 
variety of artificial molecular scaffolds (10 -13).  
Annually many people die worldwide of liver cancer following hepatitis B. The 
functional imaging of liver ASGP-R is of both diagnostic and prognostic value during 
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treatment of liver cancer and other liver conditions (14 -16). Molecular constructs bearing 
efficient reporter groups and pendant β-galactoside and/or N-Acetyl-β-galactosaminyl 
residues can lead to hepatocyte-specific imaging agents for liver (11, 14 -16). A conjugate 
of a neoglycoprotein, galactosylated serum albumin (GSA), with 99mTc-DTPA (diethylene 
triamine pentaacetic acid) ([99mTc]-DTPA-GSA), has been used in SPECT (single photon 
emission computed tomography) hepatic imaging to assess the ASGP-R function in mice 
(17). The hepatocyte-specific nature of the ASGP-R and the fact that it is still expressed 
(although in reduced numbers) on hepatoma cells makes it possible to detect liver cancer 
metastases to other organs. The same imaging agent, ([99mTc]-DTPA-GSA), has been 
demonstrated clinically useful in humans to detect liver cancer metastases to the bones (18) 
and to assess de dynamics of the ASGP-R internalisation/recycling to the surface of the 
hepatocytes (19, 20). A Gd-DTPA conjugate of polylysine (PL) derivatized with galactosyl 
groups (Gd-DTPA-gal-PL) (21), as well as a spin-labeled arabinogalactan (22), have also 
been developed as macromolecular potential contrast agents for liver MRI by targeting the 
hepatocyte ASGP-R. A variety of particulate systems targeted to the ASGP-R have also 
been tested in cells and mice as potential contrast agents for liver MRI: monocrystalline 
iron oxide nanoparticles (MION) conjugated to the bovine plasma protein asialofetuin 
(ASF), (MION-ASF) (23), arabinogalactan (AG)-coated ultra-small superparamagnetic 
iron oxide particles (USPIO), (AG-USPIO) (24 -27). Both the macromolecular and 
particle-based ASGP-R-targeted imaging agents described above, include carriers bearing 
multiple reporter groups and a multivalent display of galactosyl targeting groups. However 
these agents are inherently polydisperse and ill characterised. Chemically well-defined and 
characterised multivalent agents can be assembled by an alternative molecular design: the 
conjugation of dendrimeric clustered carbohydrate bifunctional reagents (monodisperse, 
well defined and characterised) to a reporter group (28). The resulting conjugates are of 
substantially lower molecular weight, higher stability and greater biological safety. 
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Previous to our report on the synthesis of dendrimeric multivalent glycoconjugates of 
metal complexes for molecular imaging (MRI and scintigraphy) (29, 30), only a study 
describing the use of a low molecular weight, well characterized, monomeric [111In]-
radiolabeled galactopyranosyl conjugate of DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) for the targeting of the ASGP-R both in hepatic cell lines and 
mice had appeared in the literature (31). The design of lectin-targeted MRI imaging agents 
includes a reporter group, consisting of a chelator binding lanthanide(III) ions with high 
kinetic and thermodynamic stability, and a targeting group consisting of a clustered 
carbohydrate of variable valence, containing an increasing number of terminal galactosyl 
groups, capable of interacting with high affinity and selectivity with endogenous lectins 
such as the ASGP-R (3, 29, 30).  
Here we report the radiolabeling of a series of glycoconjugates based on DOTA-
monoamide and bisamide functionalized chelators (Fig. 1) with [153Sm]3+ and their 
evaluation using in vitro studies in the human hepatocyte carcinoma cell line Hep G2. 
DOTA-like chelators are well known to form lanthanide(III) chelates of high 
thermodynamic and kinetic stability, which is of crucial importance for in vivo applications 
(32). Dynamic gamma-scintigraphic studies of the pharmacokinetics of the [153Sm]3+-
labeled glycoconjugates and their biodistribution in Wistar rats are also described, 
revealing the effect of valence and type of the terminal sugar moiety on their liver targeting 
efficacy. We also report an in vivo MRI study of the contrast effects and pharmacokinetics 
of the Gd3+ complexes of the divalent glycoconjugates DOTAGal2 (2a), DOTAGlc2 (2b) 
and DOTALac2 (2c) (Fig. 1) in mice, compared with a typical commercial, small molecular 
weight contrast agent, GdDTPA (Magnevist®). 
EXPERIMENTAL  
The synthesis of the monovalent DOTAGal, DOTALac and DOTAGlc (1), divalent 
DOTAGal2, DOTALac2 and DOTAGlc2 (2) and tetravalent DOTAGal4 (4) monoamide 
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glycoconjugate ligands (29), as well as of the divalent DO2A(cis)Gal2 bisamide (3) ligand 
(Torres S, Martins JA, André JP, Neves M, Santos AC, Prata MIM, Geraldes CFGC, 
Radiochimica Acta, submitted), have been described previously. 
Reagents for cell interaction, gamma imaging and biodistribution studies 
[153Sm]Samarium chloride ([153Sm]Cl3) was produced at the ITN (Instituto 
Tecnológico e Nuclear), Lisbon, with a specific activity >5 GBq/mg. For this purpose, 
[153Sm] samarium oxide ([153Sm]2O3) was prepared from a 98% [152Sm] enriched 
samarium oxide target, sealed into a quartz vial and welded into an aluminium can, by 
neutron irradiation using a thermal flux of 2.3 x 1013 n/cm2 s. Following irradiation, the 
sample was opened, dissolved in 1N HCl and the final [153Sm]samarium chloride 
(153SmCl3) was brought to a stock concentration of 1.9 x 10-3 M. 
Radiotracer preparation 
In initial experiments, stock solutions of the ligands were prepared in isotonic HEPES 
(0.1 M 1-piperazineethane sulfonic acid, 4-(2-hydroxyethyl)- monosodium salt) buffer (pH 7), 
mixed with [153Sm]samarium chloride and the solution was heated at 60° for 3 h. After 
verifying that that the radiolabeling of the ligands is more efficient at lower pH (to promote 
the deprotonation of the binding groups), the definitive experiments were carried out using 
sodium acetate buffer (0.4 M, pH 5). A quality control was performed by thin layer 
chromatography (TLC), using water: ethanol: dicloromethane: ammonia, 5: 5: 5: 1, as eluent. 
Serum stability 
To 3 mL of fresh human serum previously equilibrated in a 5% CO2 (95% air) 
environment at 37°C, was added 5 µCi of the [153Sm]DOTAGal standard solution. The 
mixture was stored in a 37°C environment. At appropriate periods of time (0, 30 min, 1 h 
and 4 h) 100 µL aliquots (in triplicate) were removed and treated with 200 µL of ethanol. 
Samples were then cooled (4°C) and centrifuged for 15 min, at 4000 rpm and 4°C, to 
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precipitate serum proteins. 100 µL of supernatant was removed for activity counting in a γ 
well-counter. The sediment was washed twice with 1 mL of ethanol and counted. The 
activities in the supernatant and in the pellet were compared as (activity in the pellet/ 
activity in supernatant) ∗100. 
In vitro cell interaction studies 
Hep G2 human hepatoma cell line (ECACC, United Kingdom) was grown in 75 mL 
bottles with MEM (minimum essential medium) from Sigma, which contains 18 mM CaCl2, 
supplemented with 10% FBS (fetal bovine serum) from Gibco Invitrogen, and non-essential 
aminoacids, glutamine and penicillin/streptomycin, all from Sigma. The cells were counted 
and transferred to a 6-hole multiwell plate (0.2 million cells/hole), 2 mL of medium were 
added to each hole and then the cells were incubated at 37 °C, under 5% CO2 for the period 
necessary to obtain cell confluence. This is needed because the human hepatocyte carcinoma 
line Hep G2 expresses maximum receptor activity only in confluent cultures (33). The 
medium was changed every day. In the day of the experiments the medium was removed and 
the cells were washed twice with 1.5 mL of medium before adding 1.2 mL of medium and 
they were allowed to adjust for 1 h at 37 °C. Approximately 1 µCi of radiolabeled ligand was 
added in each well to the medium and the cells were incubated for 30 min, 1 h and 2 h at 37 
°C. To three of the holes in each plate an excess of asialofetuin (Sigma) (200 µL of a 0.2 
mg/mL solution) (31) was added simultaneously with the radiolabeled ligand in order to 
evaluate the contribution of non-specific contributions to the cell uptake of the 
glycoconjugates. At appropriate time periods the experiment was stopped by removal of the 
medium and washing the cells twice with 750 µL ice-cold phosphate buffered saline. The 
medium plus PBS was collected to tubes to measure the radioactivity. Finally, the cells were 
treated with 1 N NaOH (1 mL) and incubated at 37 °C for 10 min, to detach them from the 
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plates, and the radioactivity was measured in a γ-counter. Each experiment was carried out 
simultaneously in triplicate. 
In vivo gamma imaging 
A gamma camera-computer system (GE 400 GenieAcq, from General Electric, 
Milwaukee, USA) was used for acquisition and pre-processing. Data processing and 
display were performed on a personal computer using homemade software developed for 
the IDL 5.2 computer tool. A well counter (DPC-Gamma C12, LA, USA) with a Compaq 
DeskPro compatible computer was used for activity counting in the biodistribution studies.  
Gamma images and biological distribution for the [153Sm]3+complexes were 
determined using (200-250 g) Wistar rats. All animal studies were carried out in 
compliance with procedures approved by the appropriate institutional review committees. 
Conscious rats were allowed free access of food and water ad libitum. Groups of four 
animals (one group for each complex) were anaesthetized with Ketamine (50 mg/ml) 
/chloropromazine (2.5%) (10:3) and injected in the femoral vein with ca. 400 µCi of the 
respective [153Sm]3+chelate. The animals were then positioned in dorsal decubitus over the 
detector. Image acquisition was initiated immediately after radiotracer injection. Sequences 
of 180 images (of ten seconds each), were acquired to 64×64 matrices. In addition, static 
data were acquired 24 h after the radiotracer injection. 
Images were subsequently processed using an IDL based program (Interactive Data 
Language, Research Systems, Boulder, CO, USA). In order to analyze the transport of 
radiotracer over time, three regions of interest (ROI) were drawn on the image files, 
corresponding to the thorax, liver and left kidney. From these regions, time-activity curves 
were obtained. 
Biodistribution studies  
Groups of four animals were injected in the tail vein with ca. 100 µCi of the respective 
[153Sm]3+ tracer and sacrificed 1 h later. The major organs were excised, weighted and tissue 
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radioactivity measured in a γ well-counter. Similar biodistribution studies were also 
performed with the animals referred in the previous section sacrificed at 24 h. For 
determination of non-specific uptake on receptor-positive organs, a group of four animals was 
co-injected in the femoral vein with a solution of asialofetuin in NaCl (2 mg/mL) (injected 
volume, 200 µL, 0.2 mg asialofetuin/100 g body weight) and [153Sm]3+-DOTAGal2 (200 µL).  
Magnetic resonance imaging  
The MRI experiments were performed on a Bruker Pharmascan system (Bruker 
Medical Gmbh, Ettlingen, Germany) using a 7.0-T horizontal-bore superconducting magnet, 
equipped with a 1H selective birdcage resonator of 38 mm and a Bruker gradient insert with 
90 mm of diameter (maximum intensity 300 mT/m). All the data were acquired using a 
Hewlett-Packard console running Paravision software (Bruker Medical Gmbh, Ettlingen, 
Germany) operating on a Linux platform. All MRI studies were performed in accordance with 
the Spanish law for animal protection. In vivo experiments were performed on albine Swiss 
male mice, weighing 19-26 g. One animal was measured by MRI for each compound tested. 
Anesthesia was initiated by inhalation in an induction box with O2 (1 l/min) containing 3 % of 
isofluorane, and maintained during the experiment employing a mask and 1-2 % of 
isofluorane in O2. The mice were taped down gently into a holder, to minimize breathing-
related motion, and were then placed in a heated probe, which maintained the core body 
temperature at approx. 37 ºC, monitored by a rectal probe. The physiological state of the 
animal was monitored by a Biotrig physiological monitor (Bruker Medical Gmbh, Ettlingen, 
Germany) using the respiratory rate and body temperature. The contrast agents were injected 
as a bolus of 50 µl via a tail vein catheter at a dose of 0.3 mmol Gd Kg-1 BW, except for 
GdDTPA (Magnevist®, Schering AG, Berlin, Germany) where a dose of 0.2 mmol Gd kg-1 
BW was used.  
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For anatomical reference, a multi-slice rapid acquisition and relaxation enhancement 
(RARE) sequence (34) was performed with the following parameters: RARE factor = 8, TR = 
4000 ms, effective TE = 65 ms, averages = 2, 6 coronal slices, slice thickness 1.2 mm, FOV = 
3.8 cm, matrix = 256 x 256. Then, regional contrast agent uptake was assessed. A series of T1-
weighted spin echo images were sequentially acquired over one hour following the injection 
of the contrast agent. The acquisition parameters were: TR = 155 ms, TE = 11.76 ms, 
averages = 2, 6 coronal slices, slice thickness 1.2 mm, FOV = 3.8 cm, matrix = 256 x 256, 60 
repetitions with temporal resolution 59.31 s. 
MRI Data processing  
Data were analyzed with software written in house in IDL. With the aim of comparing the 
pharmacokinetics obtained from different animals, the data were normalized by calculating 
the relative, rather than the absolute, enhancement (RE):  
   100)(
0
0 ×−=
I
IIRE  
 where I is the signal intensity at any given time after CA injection and I0 is the 
intensity before injection.  
Pharmacokinetics were analyzed by calculating the average enhancements within two 
different ROIs placed on the liver, kidney medulla, kidney cortex and muscle.  
Statistical Analysis 
All the data obtained in the biodistribution and cell experiments are expressed as means ±  
standard deviation (SD). For the cell studies results a two tailed t-test was employed to 
evaluate the signficance of differences of individual pairs of values, and p < 0.05 was 
considere significant. 
RESULTS AND DISCUSSION 
Studies of [153Sm]3+-radiolabeled glycoconjugates 
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Quality control analysis: All the radioactive complexes where analysed by TLC  for 
radiochemical purity determination as described in the Experimental section. The 
radiochemical purity was > 98 % for all the [153Sm3+] complexes with a specific activity ca 
2mCi/µmol. 
Stability in Serum. The percentage of radioactivity in the non-proteic fraction of human 
serum incubated with 5 µCi of the [153Sm]3+-labeled chelates slowly decays as a function 
of time (data not shown). For example, in the case of [153Sm]3+-DOTAGal ca 90 % of the 
activity remained in the non-proteic fraction after 4 hours.  
Cell uptake. The Hep G2 human hepatocyte carcinoma cell line is known to express 
ASGP-R both in vivo and in vitro (32, 34). Fig. 2 shows the time dependence of the 
radioligand [153Sm]3+-DOTAGal2 uptake in Hep G2 at 37°C with and without ASGP-R 
blocking, studied in a MEM medium containing 16 mM CaCl2. In these conditions, 
unblocked cell uptake increases with time, reaching 12.6 % of the added activity after 2 h, 
but without reaching a plateau within the 2 h of incubation. The in vitro cell uptake of the 
radioligand activity was reduced in the presence of an excess of the ASGP-R blocker 
asialofetuin, but much less than expected from ASGP-R mediated specific uptake of the 
radioligand in these ASGP-R rich cells, especially at short incubation times (31). (Fig. 2). 
The non-blocked and blocked internalization values are at the limit of significant 
difference at the short times 30 min and 60 min (ratios of 1.4 and 1.2, respectively), as 
indicated by a value of p > 0.04 using the two tailed t–test, and are significantly different at 
2 h (p = 0.002), when the non-blocked/blocked ratio reaches a maximum value of 2.3. Hep 
G2 cell uptake studies of an [111In]3+- labeled DOTA-Gal monoamide, using a RPMI-1640 
medium containing 50 µM CaCl2, gave a 3.1 ratio of non-blocked/blocked uptake at 30 
min (31). The discrepancy between the two studies at low incubation times could be 
attributed to the larger concentration of CaCl2 in the cell medium used in the present study, 
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although the litterature study, which used much lower CaCl2 concentration also reported 
that ion baseline uptake was drastically reduced in the absence of Ca2+ (31). 
In vivo gamma imaging and biodistribution. Fig. 3 shows scintigraphic images of Wistar 
rats obtained 30 minutes after tracer injection for [153Sm]3+-labeled DOTAGal2 (2a) and 
DOTAGlc2 (2b) conjugates, selected from dynamic acquisitions consisting of frames 
obteined at every 10 seconds. At 30 minutes, there is a noticeably high uptake of [153Sm]3+-
DOTAGal2 by liver (left image), correlating with the fact that the surface of liver 
parenchimal cells contain a very high density of ASGP-R, about 500,000 per cell (36, 37), 
which can selectively take up the radiotracer by receptor mediated endocytosis (31). In the 
left image the bladder is also seen, which reflects the renal excretion pathway of these 
hydrophilic compounds. In addition, a very rapid clearance occurs from all other organs, 
including the kidneys, in accordance with the biodistribution data obtained in the same 
animals (see below). A quite different behaviour is found in rats injected with [153Sm]3+-
DOTAGlc2 (right image), as the 30 minutes activity is localized almost exclusively in the 
bladder. Virtually no liver uptake is observed, which is consistent with the fact that 
glucosyl glycoconjugates are not recognized by the ASGP-Rs (38). The time/activity 
curves for the [153Sm]3+-labeled glycoconjugates were obtained from the dynamic 
acquisition experiments (Fig. 4). The curves were smoothed and normalized in relation to 
the maximum activity obtained for each radiolabeled glycoconjugate. The kidneys are well 
visible in the images at early times, allowing the definition of their ROIs. The time/activity 
kidney curves of Fig. 4 correspond to the left kidney but the profile is similar for both 
kidneys. While the activity of [153Sm]3+-DOTAGal2 is higher in the liver than in the 
kidney, and steadily increases up to the 30 minutes time interval in both organs, the 
activity of [153Sm]3+-DOTAGlc2 quickly rises in kidney to a much higher value than in 
liver, reaching a maximum at 5 minutes, and later decays slowly. The initial behaviour of 
[153Sm]3+-DOTALac2, with a quick activity increase in kidney, is close to that of [153Sm]3+-
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DOTAGlc2, but after attaining a maximum at 4 minutes, the kidney activity quickly 
decreases, while the liver activity steadily rises, like in [153Sm]3+-DOTAGal2. This result 
might be explained by the higher hydrophilicity of the lactosyl conjugate relative to the 
galactosyl conjugate, which determines its initial concentration in the kidney, after which 
the terminal galactosyl groups of the lactosyl derivative binds to the liver ASGP-Rs. A 
number of lactosyl conjugates have been described for liver targeting (40, 41).  
Biodistribution data for the [153Sm]3+-radiolabeled glycoconjugates obtained in 
Wistar rats are presented in Figs. 5 and 6 and Table 1 as percentage of injected dose per 
gram of tissue (% ID/g). The most striking feature shown by the biodistribution studies at 
one hour post-injection is the high liver targeting ability of the galactosyl conjugates (Fig. 
5a). In sharp contrast, the glucosyl conjugates show no liver uptake, as they locate mainly 
in the kidneys due to their hydrophilicity. The biodistribution data for the lactosyl 
conjugates confirm the intermediate behaviour between the galactosyl and glucosyl 
conjugates seen in the dynamic acquisition curves described above.  
Another noteworthy finding is the effect of the valence of the glycoconjugates on the 
biodistribution pattern. Whereas the monovalent conjugate [153Sm]3+-DOTAGal shows 
some spleen and lung uptake, the divalent compound, apart from the kidney, does not 
appear in a significant extent in any other organ. The behaviour of the tetravalent 
compound is very similar to that of the divalent one (e.g. liver uptake corresponds to 0.91 
% of the ID/g for [153Sm]-DOTAGal2 and to 0.82 % of the ID/g for [153Sm]3+-DOTAGal4), 
indicating that the effect of the increase in valence from two to four does not seem to 
improve liver uptake after one hour. This might be explained by the high number of 
ASGP-Rs expressed by each hepatocyte cell (36, 37) and/or some degree of steric 
crowding of the galactose residues. However, the effect of the valence of synthetic and 
natural glycoconjugates on the affinity to lectins has been fully demonstrated (7, 8) and 
thus the expected order of increasing affinity of the glycoconjugate ligands for the ASGP-
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R is tetra>tri>di>mono (7, 8, 41, 42). This is confirmed by the observed contrast in the 
biodistribution behaviour between the [153Sm]3+-DOTAGal2 and [153Sm]3+-DOTAGal4 
derivatives after 24 hours (Fig. 5b, Table 1). The activity remaining on liver at 24 hours for 
the tetravalent radiolabeled glycoconjugate [153Sm]3+-DOTAGal4 (0.2 % of the ID/g) is 
much higher than for the divalent 153Sm3+-DOTAGal2 (0.002 % of the ID/g), suggesting a 
greater metabolic stability of the former compound.  
The data in Fig. 5a also shows that the three ligands bearing only one sugar moiety 
(DOTAGal, DOTAGlc and DOTALac) stay longer in the blood stream and have a more 
dispersed biodistribution pattern than the higher valence analogs. Binding to some plasma 
component might be responsible for this finding. Thus, in addition to the multivalence 
effect, subtle structural effects arising from the dendrimeric framework of these ligands, 
especially the tertiary amine nitrogen, might be responsible for the observed differences of 
biodistribution between the monovalent and multivalent compounds. 
Fig. 5c shows the bioditribution results of an in vivo competition experiment using 
large excess of asialofetuin, a specific blocker of the ASGP-R, co-injected with the 
radioligand [153Sm]3+-DOTAGal2. In animals injected with the blocker, activity uptake in 
liver was reduced by 90 % (p < 0.001) compared with the blocked animals (31). The 
injection of the blocking dose also increased the uptake in the kidneys by a factor of three, 
suggesting that more activity is cleared instead of binding to the ASGP-R. These results 
strongly suggest that the in vivo uptake of the radiolabeled glycoconjugate is specific to the 
ASGP-R endocytosis. These in vivo results give a much higher 1 hour non-
blocked/blocked uptake ratio of 9 that obtained for the Hep G2 cell line in vitro, even at 2 
hours. This could in part result from the high Ca2+ concentrations in the cell medium used 
in the later studies and also from the fact that the total number of ASGP-R receptors in the 
human hepatocyte carcinoma cell line HepG2 is 140,000 +/- 65,000 sites per cell (43), 
significantly lower than the value obtained for isolated rat hepatocytes (36, 37). 
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A DOTA bisamide glycoconjugate bearing two galactosyl moieties in a cis position, 
DO2A(cis)Gal2 (Fig. 1) was also evaluated. Fig. 6 compares the biodistribution of this 
radiolabeled ligand in Wistar rats at one hour post-injection with that of DO3AGal2. It 
shows that the two different topologies of the targeting groups do not change their very 
marked preference for preferential liver uptake, but the radiolabeled DO2A(cis)Gal2 
compound shows only half liver enhancement of the DOTA monoamide conjugate, 
indicating reduced liver targeting ability. 
Magnetic resonance imaging 
Effect of the Gd chelates on vital functions. The CAs are well tolerated by the mice. No 
gross side effects were observed during injection, immediately or after the experiment. The 
animal temperature remained stable throughout the entire experiment, whereas the 
respiration rate slightly increased during the first 2-3 minutes post-injection.  
MRI in vivo. Series of T1-weighted spin echo images of the dynamic contrast enhanced 
(DCE) MRI experiments with the three divalent DOTA-glycoconjugate chelates of Gd3+, 
GdDOTALac2, GdDOTAGal2 and GdDOTAGlc2 (dose 0.3 mmol kg-1 BW), and GdDTPA 
(dose 0.2 mmol kg-1 BW), are shown in Fig. 7. Before injection, kidney, liver and muscle 
did not show any contrast difference, due to the short TR (155 ms) used for the acquisition 
of the T1-weigthed images. After injection, a strong signal enhancement was observed in 
the kidneys and vena cava, for the various CAs, as a result of the T1 shortening. A slighter 
signal enhancement was observed in liver and muscle for all the CAs.  
The time course of the averaged signal intensity of several ROIs of the T1-weighted 
spin echo MR post- contrast images obtained for the different CAs, normalized to the 
respective intensities of the pre-contrast images, are displayed in Fig. 8. The scattering in 
the curves was caused by animal respiratory motion. The time course of the averaged 
enhancement after the injection of 0.2 mmol/kg of GdDTPA (Fig. 8a) is in good agreement 
with the literature (44). The signal enhancement increased immediately after injection from 
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0 up to about 300 % in the kidney medulla and about 150 % in the kidney cortex, liver and 
muscle. While the enhancement in the later organs remained constant for about 40 min, the 
kidney medulla value slowly decreased in that time interval to about 200 %. The kidney 
medulla/liver enhancement ratio decreased from 2.2 at 4 minutes to 1.5 at 35 minutes. 
After injection of GdDOTALac2 (Fig. 8b), the relative enhancement increased up to 
approx. 350 % in the kidney medulla, 260 % in the kidney cortex, 300 % in the liver and 
180 % in the muscle. These maximum enhancements were reached at 20, 10, 3-4 and 4-5 
minutes post-injection, respectively, and then decreased slowly. The kidney medulla/liver 
enhancement ratio increased from 0.6 at 4 minutes to 4.1 at 35 minutes. In the case of 
GdDOTAGal2 (Fig. 8c), more moderate signal enhancements were observed in all the 
organs. The relative enhancement increase was approx. 220 % in the kidney medulla, 150 
% in the kidney cortex, 100 % in the liver and 80 % in the muscle. In all ROIs a plateau 
was reached within the first 5 minutes post-injection and remained constant until the end of 
the pharmacokinetics experiment, with a constant kidney medulla/liver enhancement ratio 
of 1.7. Finally, immediately after the injection of GdDOTAGlc2 (Fig. 8d) a very strong 
signal rise was observed in the kidney cortex, medulla and liver, followed after 3 minutes 
by signal decay, especially in the kidney cortex and medulla, due to an effect of T2 
shortening induced by the extremely high concentration of the CA. This circumstance did 
not allow the maximum enhancement to be measured. Nevertheless, from the measurable 
points the kidney medulla/liver enhancement ratio increased from 1.6 at 3 minutes to 5.3 at 
35 minutes. 
This qualitative comparison of the pharmacokinetics data of the four compounds 
shows that the glycoconjugate chelates GdDOTAGlc2 and GdDOTAGal2 behave quite 
similarly to GdDTPA throughout the whole time course of the experiment, with 
predominant kidney enhancement. In the case of GdDOTALac2 the initial enhancement of 
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liver is higher than of kidney, but after 4 minutes the kidney cortex and medulla effect 
becomes predominant. 
 Although the r1 relaxivities at 300 MHz (7.0 T) and 37 ºC of the CAs used in this work 
have not been published, the estimated values from their published NMRD curves and the 
respective fitting parameters are r1 = 7.0 mM-1.s-1 for GdDOTAGal2 and GdDOTAGlc2 and r1 
= 8.0 mM-1.s-1 for GdDOTALac2 (29), and r1 = 4.0 mM-1.s-1 for GdDTPA (45). The r2/r1 ratio 
should be 7/6, giving in each case r2 values 16 % higher than r1. The gadolinium 
concentration time courses for each ROI were not calculated from the T1-weighted image 
intensities, as there is no garantee that the in vitro and tissue relaxivities of the compounds are 
the same. However, the ratio of the product (r1 x dose) is 2.6 for GdDOTAGal2 and 
GdDOTAGlc2 versus GdDTPA and 3.0 for GdDOTALac2 versus GdDTPA. These values are 
much larger than the ratios of the maximum image intensity enhancements attained by those 
CAs relative to GdDTPA, which are 0.7 – 0.9 for the kidney medulla and 1.3 – 1.6 for the 
cortex (Fig. 8) (GdDOTAGlc2 is excluded because its maximum T1 enhancement effect could 
not be measured, as discussed above). This shows that the maximum concentration/dose ratio 
attained in the kidneys by the Gd3+- based CAs is considerably lower than for GdDTPA, 
indicating that part of the injected CAs become T1 contrast-silent, presumably when taken up 
into the liver. Such a considerable uptake of the galacosyl containing chelates was 
demonstrated by the gamma scintigraphic and biodistribution studies of the [153Sm]3+-labeled 
ligands. 
CONCLUSIONS 
Hepatobiliary CAs, with selective hepatocyte uptake by organic anion carriers and 
biliary excretion, provide a means of obtaining specific liver MRI enhancement and 
improved detection and characterization of small hepatic lesions (46). Several potential 
CAs for liver MRI have also been developed by targeting the hepatocyte ASGP-R and 
uptake via its endocytic pathway, such as targeted particulate T2 relaxation agents (23, 27) 
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and macromolecular T1 relaxation agents (21, 22). This approach is also useful in the 
detection and characterization of hepatic lesions, as they strongly affect the hepatocyte 
receptor levels (21). Appending a small glycodendrimer ending with galactosyl unit(s) to a 
GdDOTA scaffold via an amide bond generates a new class of low molecular weight, 
stable, hydrophilic glycoconjugates, of greater biological safety than the polymeric Gd-
DTPA-gal-PL (21), and with targeting ability for the liver via recognition of the ASGP-R, 
as suggested in vitro by Hep G2 cell uptake, and specially in vivo gamma-imaging and 
biodistribution studies of the [153Sm]3+-labeled compounds in Wistar rats. The 
glycodendrimer architecture allows variation of the sugar type and valence in an interactive 
way from a reduced number of building blocks. The effect of the increase of valence on the 
targeting efficiency is clear when going from monoderivatives to divalent glycoconjugates. 
The performance of the next generation, tetravalent glycoconjugates, is similar to that of 
the divalent one, at one hour post-injection. However this compound is retained much 
longer at its target organ, as demonstrated by the activity remaining in the liver after 24 
hours. Moreover, there are important biodistribution differences between mono- and 
multivalent glycoconjugates (31). A critical feature in the glycoconjugate-ASGP-R 
interaction is the topology of both the glycoconjugate and lectin. In this respect, the 
relative orientation and spacing of the carbohydrate residues in the glycoconjugate in 
relation to the distribution of the Carbohydrate Recognition Domains (CRDs) on the 
ASGP-R is of fundamental importance in the optimization of their interaction (47, 48). 
The superior performance of the multivalent compounds validates our approach to 
lectin-mediated targeting for molecular imaging. The specific uptake of the galactosyl-
bearing compounds via the ASGP-R opened an opportunity for the use of their Gd3+ 
chelates as CAs for ASGP-R mediated liver MRI. However, despite the promising 
scintigraphic performance of the galactosyl-bearing multivalent compounds, the animal 
MRI assessment of the corresponding Gd3+ chelates shows only limited liver-to-kidney 
 20
contrast effects, similar to the GdDTPA effects. We found evidence that the maximum 
concentration/dose ratio attained in the kidneys by the Gd3+- based CAs is considerably 
lower than for GdDTPA, indicating that part of the injected CAs become T1 contrast-silent, 
presumably when taken up into the liver. It is possible that the T1 shortening effect of the 
Gd3+-labeled Gal-containing compounds is strongly diminished upon hepatocyte 
internalization into an endossomic vesicle via receptor-mediated endocytosis of the ASGP-
R. Several studies have shown that the molar relaxivity r1 of a CA is strongly reduced upon 
uptake into an intracellular compartment (49-51), which restricts the efficiency of 
extracellular water exchange with the paramagnetic center in the vesicle compartments 
through the cytoplasm due to the effects of the membranes (51). As opposed to cell 
internalization into the cytoplasm by electroporation, where the observed relaxation rates 
are proportional to the amount of internalized paramagnetic complex, internalization into 
intracellular vesicles quenches the relaxation enhancement to a plateau value (about 3 s-1) 
when the entrapped amount of Gd3+-chelate is higher than 1 x 1010 Gd/cell (51).  
The fast kidney uptake of these highly hydrophilic complexes will also limit the 
extent to which they can be concentrated within the hepatocytes up to a concentration high 
enough to yield a detectable image contrast (52), limiting their use as CAs for ASGP-R -
mediated molecular imaging. The design of more efficient hepatocyte-target MRI agents of 
this kind may be pursued by tuning the hydrophilicity/hydrophobicity balance of the 
dendrimeric compounds, through either structural modification of the dendrimeric 
backbone or the sugar-linker moiety, while improving the targeting ability of the 
multivalent architecture, and enhancing their relaxivity by centrally positioning the Gd3+ to 
provide a more effective motional coupling of the chelate with the Gd3+-proton vector (53). 
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Table 1 – Biodistribution of [153Sm]3+-DOTA glycoconjugates at 1 h and 24 h post-
injection in Wistar rats. Results are expressed as percentage of injected dose per gram of 
tissue and are the mean of groups of  four animals. 
 
 
 
Tissue Glc2(2b) 
1h 
Lac2(2c) 
1h 
Gal (1a) 
1h 
Gal2 (2a) 
      1h                     24h 
Gal4(3) 
1h                      24h 
Blood 0.002± 5X10-4 0.015±0.005 0.158±0.01 0.057±9X10-4              5X10-5±2X10-5 0.028±8X10-4            1X10-4±4X10-5
Kidney 1.48±0.001 1.13±0.240 0.0540±0.01 0.075±0.009                   0.007±5X10-5 0.091±0.015                 0.022±0.007
Liver 0.011±0.002 0.106±0.011 0.66±0.09 0.9062±0.073                 0.023±3X10-4 0.428±0.035                 0.201±0.008
Spleen 0.012±0.003 0.046±0.002 0.49±0.12 0.012± 0.006                 0.003±2X10-6 0.006±0.0005                0.020±0.001
Heart 0.006±0.0006 0.047±2X10-4 0.026±0.0006 0.0138±0.006               2X10-4±6X10-4 0.010±0.0022              0.002±4X10-4
Lung 0.022±0.0002 0.051±0.003 0.1590±0.003 0.008±0.002                5X10-4±3X10-6 0.027±0.008               0.002±0.0002
S.Intest 0.009±5X10-4 0.025±0.016 0.0110±0.005 0.0167±0.0084            3X10-4±2X10-5 0.021±0.0021              0.002±4X10-4
L.Intest 0.014±0.0027 0.029±0.017 0.011±0.004 0.0029±0.001               6X10-4±3X10-6 0.013±0.0018             0.003±6X10-4
Stomach 0.0190±0.004 0.004±0.002 0.012±0.0001 0.0121±0.005               4X10-4±2X10-5 0.014±0.0018             0.002±7X10-4
Brain 3X10-4±2X10-5 2X10-4±9X10-5 3X10-4±0.0005 0.0007± 0.0002            6X10-5±6X10-6 4X10-4±1X10-4         2X10-5±4X10-6
